ENTA Stock Discussion
Enanta Pharmaceuticals, Inc. Description
Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection. The company also develops EDP-788, an intravenous drug for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. and Abbott Laboratories. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Industry: Biotechnology
Keywords: Biotechnology Infectious Diseases Chemical Compounds Infection Medical Research Viruses Hepatitis C Hepatitis C Virus HCV Staphylococcus Aureus Treatment Of Hepatitis Cyclophilin Cyclopropanes Methicillin HCV Infection Pyrrolidines
Recent Comments
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
- ZealousTrout235 on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
- TraderMike on Market Recap for Tuesday, May 21, 2024
- CharmingMole371 on Market Recap for Tuesday, May 21, 2024
- TraderMike on IZM
From the Blog
Popular Now
Featured Articles